Human studies of Listeria monocytogenes vectors

单核细胞增生李斯特氏菌载体的人体研究

• 批准号: 6763110
• 负责人: ELIZABETH L. HOHMANN
• 金额: $ 39.38万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-15 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6763110
• 关键词: Listeria; attenuated microorganism; bacterial vaccines; biotechnology; cellular immunity; chimeric proteins; clinical research; clinical trials; dosage; drug screening /evaluation; enzyme linked immunosorbent assay; experimental designs; flow cytometry; gag protein; genetic manipulation; genetic strain; human subject; immunotherapy; laboratory mouse; molecular cloning; tissue /cell culture; transfection /expression vector; vaccine development; vector vaccine

DESCRIPTION: (Provided by Applicant) Listeria monocytogenes are Gram-positive intracellular bacteria which stimulate cellular immune responses, those necessary for elimination of viruses. Engineered L. monocytogenes are effective vaccine vectors for delivery of both viral and tumor antigens in animals. Both therapeutic and prophylactic approaches are successful in animals. Listeria spp. Are present in foods, enter the body through the intestine and may disseminate to cause serious infection with a tropism for the central nervous system and placenta. Safety is therefore a major consideration in use of L. monocytogenes as a vector in humans. We have initiated (to our knowledge) the first safety study of a live attenuated L. monocytogenes vector organism in human volunteers. A highly attenuated derivative of L. monocytogenes 10403S deleted for the virulence elements actA and plcB is being studied. There have been no serious adverse events to date in 18 volunteers who received single oral escalating doses of this attenuated strain (10E5 to 10E9 colony forming units). This proposal sets forth a plan for ongoing evaluation of Listeria bacteria as vaccine vectors in humans. Attenuated L. monocytogenes will be engineered to express defined influenza A and HIV Gag epitopes as secreted fusion proteins of listeriolysin. Strains constructed will be evaluated bacteriologically, in mice and in tissue culture systems. Promising strains will be carried on for evaluation in small inpatient clinical studies designed to evaluate safety, shedding and human immunogenicity. Contemporary immunological studies using tetramer, FACS and ELISPOT technologies will be used to determine whether discrete human cellular immune responses to vectored viral antigens can be detected in humans after these investigational immunizations. These studies will provide important data on the feasibility and utility of using Listeria monocytogenes vectors in humans.

说明：（申请人提供）单核细胞增生李斯特菌为革兰氏阳性